$0.04
-0.01 (-20.41%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LIANY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 2 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaNCT06206278Objective response rate (ORR)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business Reason | Drug: Infigratinib | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 6 | 2024-05-31actual | 2024-08-14 |
| Phase I Study of the BBP-398 in Patients With Advance Solid TumorsNCT05621525Determination of Maximum Tolerated Dose (MTD) of BBP-398Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business reason | Drug: BBP-398 | Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer | 7 | 2024-03-29actual | 2024-06-25 |
| BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsNCT06032936Treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business reason | Drug: BBP-398, osimertinib | NSCLC | 4 | 2024-03-29actual | 2024-06-25 |
| Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA StudyNCT05629390The proportion of participants cured based on their collarette score of 0 for the upper eyelid of the analysis eye.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Lotilaner, Vehicle Control | Blepharitis | 163 | 2023-09-15actual | 2024-05-21 |
| A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMNCT05174416results2024-09-19Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak GradientRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Mavacamten, Placebo | Obstructive Hypertrophic Cardiomyopathy | 81 | 2023-03-06actual | 2024-09-19 |
| Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsNCT05019794Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Unknown status | Drug: Infigratinib | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 80 | 2022-12-30 | 2022-06-27 |
| Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese SubjectsNCT05135871results2024-07-25Area Under the Curve (AUC) (0-last), AUC(0-inf)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Mavacamten | Hypertrophic Cardiomyopathy | 45 | 2022-02-05actual | 2024-07-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19